Business
uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding
~ Term of current $50 million debt outstanding extended from January 2027 to October 2030 ~ ~ Additional $100 million available subject to regulatory and financial milestones ~ ~ Additional $25 million available subject to Hercules’ approval ~ ~ Transaction provides financial flexibility and improves cost of capital ~ LEXINGTON, Mass. and AMSTERDAM, Sept. 24, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with
About this update from Hercules Capital, Inc.
[{"type":"image","alt":"uniQure Inc.","displaySize":"","headline":null,"caption":"uniQure Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":96,"url":"https://media.zenfs.com/en/globenewswire.com/cb8da6eec71588a1000495a1c5d28a54"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MCbXlQWdgvZoIruFbz16Zg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cb8da6eec71588a1000495a1c5d28a54","width":300,"height":96}},"lazy":false},{"type":"text","content":"~ Term of current $50 million debt outstanding extended from January 2027 to October 2030 ~","length":91,"tagName":"p"},{"type":"text","content":"~ Additional $100 million available subject to regulatory and financial milestones ~","length":84,"tagName":"p"},{"type":"text","content":"~ Additional $25 million available subject to Hercules’ approval ~","length":66,"tagName":"p"},{"type":"text","content":"~ Transaction provides financial flexibility and improves cost of capital ~","length":75,"tagName":"p"},{"type":"text","content":"LEXINGTON, Mass. and AMSTERDAM, Sept. 24, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced it entered into a $175 million non-dilutive senior secured term loan facility with Hercules Capital, Inc. (NYSE: HTGC). The transaction is designed to enhance the company’s financial flexibility to fund the potential commercial launch of AMT-130, its investigational gene therapy for the treatment of Huntington’s disease.","length":540,"tagName":"p"},{"type":"text","content":"“This non-dilutive financing keeps funds from the outstanding $50 million debt available until 2030 and provides access to an additional $125 million. We believe this transaction enhances our financial flexibility to fund the potential commercial launch of AMT-130 in the United States, anticipated in 2026,” said Christian Klemt, chief financial officer of uniQure.","length":366,"tagName":"p"},{"type":"text","content":"The loan facility consists of three tranches, including a first tranche of $50 million refinancing the current debt outstanding at closing and an additional term loan tranche of $100 million, which can be drawn at the company’s option subject to the achievement of both a regulatory milestone related t...